Fig. 1 · Structure

Documents & Downloads

Mocertatug rezetecan

B7-H4 Targeted ADC

Mocertatug rezetecan is an antibody-drug conjugate (ADC) specifically targeting the B7-H4 receptor. It demonstrates significant activity against platinum-resistant ovarian cancer and is utilized in research focused on advanced solid tumors, with particular emphasis on ovarian cancer and triple-negative breast cancer. This compound provides a valuable tool for investigating targeted therapies in oncology.

Out of Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Specifications

Manufacturer Adooq Bioscience
CAS Number 3042848-25-6
Applications B7-H4 Targeted ADC
Synonyms HS-20089; GSK5733584

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Added to your cart

View Cart Checkout
Loading...